NASDAQ:INFI - Infinity Pharmaceuticals Stock Price, Price Target & More

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) released its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.00. View Infinity Pharmaceuticals' Earnings History.

2 analysts have issued 12-month price targets for Infinity Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Infinity Pharmaceuticals' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 109.4% from the stock's current price. View Analyst Ratings for Infinity Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Infinity Pharmaceuticals include Sinovac Biotech (SVA), ZIOPHARM Oncology (ZIOP), Dermira (DERM), Unum Therapeutics (UMRX), ProMetic Life Sciences (PFSCF), Achillion Pharmaceuticals (ACHN), American Brivision (Holding) (ABVC), Syros Pharmaceuticals (SYRS), Savara (SVRA), Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Xeris Pharmaceuticals (XERS), MediciNova (MNOV), Kindred Biosciences (KIN) and Vital Therapies (VTL).

Media coverage about INFI stock has been trending somewhat positive on Saturday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a media sentiment score of 0.04 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 47.00 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Infinity Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (0.29%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok, Lawrence E Bloch, Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.

INFI stock was bought by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of INFI stock can currently be purchased for approximately $1.91.

Infinity Pharmaceuticals has a market capitalization of $111.02 million and generates $6 million in revenue each year. The biotechnology company earns $-41,830,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 22 workers across the globe.

Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]